Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4811817 | 0.86 | CYP19A1 (0.50) | PBRM1CYP19A1HDAC1HDAC6 | |
| SCHEMBL4823867 | 0.76 | TBXAS1 (0.48) | TSHRCYP19A1 | |
| SCHEMBL4815195 | 0.76 | CYP19A1 (0.50) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL6753943 | 0.71 | HMOX1 (0.53) | CYP19A1 | |
| SCHEMBL8688671 | 0.70 | PBRM1 (0.50) | PBRM1HRH3IL4I1HDAC1HDAC6 | |
| SCHEMBL4812956 | 0.70 | PBRM1 (0.55) | ALDH1A1PBRM1HRH3IL4I1 | |
| SCHEMBL4817612 | 0.69 | PBRM1 (0.45) | ALDH1A1HPGDPBRM1CYP19A1HRH3 | |
| SCHEMBL3839761 | 0.68 | PBRM1 (0.47) | ALDH1A1HPGDPBRM1HRH3IL4I1 | |
| SCHEMBL4811626 | 0.68 | HTT (0.47) | TSHRALDH1A1ALOX15HPGDPBRM1 | |
| SCHEMBL4819893 | 0.68 | CYP17A1 (0.56) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | TSHR 3172/4885ALDH1A1 3901/4885ALOX15 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.